Analyst Summary:
Xeris Biopharma Holdings, Inc., a company focused on developing and commercializing innovative products across a range of therapies, has announced its Q4 and full-year 2022 financial results. The company projects cash flow break-even in Q4 2023. Xeris has positioned itself to capitalize on growth opportunities by continuing to grow its commercial products, its partnerships and collaborations, and the advancement of the levothyroxine clinical program, while also prudently managing its cash. The company's commercial products showed strong growth in both revenue and patient demand, driven by an increase in net pricing. Xeris's levothyroxine program also showed promising results in its phase 1 study, with a phase 2 study anticipated later in 2023. The company closed the year with $102.4 million in cash, and its gross revenue increased by 52% YoY.
Forward-looking statements: Xeris Biopharma Holdings made positive statements about their company's performance and the commercialization of their products. However, investors should note that forward-looking statements are inherently uncertain and subject to various risks and uncertainties, including but not limited to the regulatory approval process, unexpected manufacturing or clinical developments, competing therapies or companies, and the global economic climate. Investors should review the company's financial statements and other disclosures, including its recently filed Quarterly Report on Form 10-Q, for more information.